<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576366</url>
  </required_header>
  <id_info>
    <org_study_id>TacDDI151010</org_study_id>
    <nct_id>NCT02576366</nct_id>
  </id_info>
  <brief_title>Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus</brief_title>
  <official_title>Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, open label crossover study with 2 treatment phases in healthy volunteers.

      The potential of phenotypic drug probes to predict drug-drug interactions between tacrolimus,
      voriconazole and rifampin will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tacrolimus area under the curve</measure>
    <time_frame>2 weeks</time_frame>
    <description>assessed twice: once after each treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Drug Interactions</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <arm_group_label>Voriconazole</arm_group_label>
    <other_name>Vfend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <arm_group_label>Rifampin</arm_group_label>
    <other_name>Rifadin; Rifadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age over 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Female

          -  Medical comorbidities

          -  Use of concomitant medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk RJ Kuypers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Vanhove, MD</last_name>
    <phone>+32 16 321002</phone>
    <email>thomasvanhove1987@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk RJ Kuypers, MD, PhD</last_name>
    <phone>+32 16 340633</phone>
    <email>dirk.kuypers@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

